Back HBV Treatment Approved HBV Drugs

Approved HBV Drugs

IDWeek 2014: Hepatitis B Relapse Is Common After Stopping Antiviral Therapy

Hepatitis B virus (HBV) rebounded in nearly 80% of people treated with fully or partially suppressive antiviral therapy using adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir), or tenofovir (Viread), indicating that long-term therapy is usually needed to control the virus, researchers reported at IDWeek 2014 last month in Philadelphia.

alt

Read more:

No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment

No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.

alt

Read more:

AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years

Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.

alt

Read more:

AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk

Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B virus (HBV) infection will develop hepatocellular carcinoma, according to findings presented this week at the 64thAASLD Liver Meeting in Washington, DC. Another study, however, found that while entecavir or tenofovir can reduce the risk, people with hepatitis B should continue to undergo regular monitoring for liver cancer, and better predictive models may be needed for Caucasian patients.

alt

Read more: